AIIMS Guwahati Reaffirms Commitment to Affordable Cancer Care Following Reduction in Prices of 137 Anti-Cancer Drugs
Source: PIB (Press Information Bureau) · Read the original ↗
Summary
AIIMS Guwahati welcomed the central government's decision to cut the maximum retail prices (MRPs) of 137 non-scheduled anti-cancer medicines by up to 70%, effective November 9, 2026. The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, carried this out through Trade Margin Rationalisation (TMR) — capping the margin between a drug's landing price and its retail price rather than fixing the price itself.
Key facts for Prelims
- NPPA: established 1997, under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
- DPCO, 2013 — Drugs (Prices Control) Order; Paragraph 19 gives government special powers over non-scheduled drug prices "in public interest."
- Trade Margin Rationalisation (TMR) regulates the margin between landing price and MRP, distinct from direct price-ceiling regulation of NLEM/scheduled drugs.
- Pharma Sahi Daam — NPPA's citizen price-transparency application.
Data and details
- 137 non-scheduled anti-cancer medicines covered; MRP cut of up to 70%, effective November 9, 2026.
- Named medicines: pembrolizumab, durvalumab (immunotherapy); osimertinib (lung cancer); bevacizumab (multiple cancers); denosumab (breast/prostate cancer); pegfilgrastim (reduces infection risk from low white-blood-cell counts during chemotherapy).
- Precedent: the 2019 TMR round covered 42 non-scheduled anti-cancer drugs with a 30% trade-margin cap.
- Estimated national savings: roughly ₹2,500 crore annually for patients.
Static–dynamic linkage
India regulates medicine prices through two parallel mechanisms: direct price-capping of "scheduled" essential drugs under the National List of Essential Medicines (NLEM), and a lighter-touch "trade margin cap" tool for non-scheduled drugs where excessive markups between manufacturer and patient — rather than the manufacturing cost itself — are the problem. This story is a live instance of the second mechanism, used specifically because high-value, patented or near-patent cancer drugs often carry very large distribution margins rather than high production costs.
Syllabus mapping: GS2 – Health policy: Affordable healthcare access; GS3 – Economy: Pharmaceutical price regulation.
Background primer
National Pharmaceutical Pricing Authority (NPPA)
- What it is:
- India's drug-price regulator.
- Founded:
- Established in 1997, functioning under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
- Members:
- An attached office of the Department of Pharmaceuticals, headed by a Chairman, with technical/pricing divisions.
- Mandate:
- Fixes and revises prices of "scheduled" formulations/bulk drugs under the Drugs (Prices Control) Order (DPCO); monitors availability of medicines; can also intervene on "non-scheduled" drug prices using special public-interest powers; runs the Pharma Sahi Daam portal/app for price transparency.
- Why it matters:
- To balance pharmaceutical industry viability against the constitutional/public-health imperative of affordable, accessible medicines.
Trade Margin Rationalisation (TMR) & DPCO, 2013
- What it is:
- A regulatory tool capping the trade margin (the gap between a drug's price-to-stockist and its MRP) rather than fixing the MRP directly.
- Founded:
- Enabled by Paragraph 19 of the Drugs (Prices Control) Order, 2013, which gives the government "extraordinary powers" to regulate even non-scheduled drug prices in the public interest; first used for 42 non-scheduled anti-cancer drugs in 2019 (capping trade margin at 30%).
- Mandate:
- Applied where high margins — not necessarily high manufacturing costs — are driving unaffordable retail prices, as is common for oncology drugs sold through a long distribution chain.
- Why it matters:
- To cut patient costs without directly setting a price ceiling that could be seen as discouraging pharmaceutical investment or innovation.
Additional context
This 2026 TMR exercise (137 drugs) expands on the 2019 precedent (42 drugs) and was based on a list recommended by an Expert Committee under the Directorate General of Health Services (DGHS), comprising oncologists and hospital/government experts — giving the policy clinical, not just economic, legitimacy. It is estimated to generate roughly ₹2,500 crore in annual savings for patients nationally.
Mains dimensions
- Affordability vs. innovation incentive: Price/margin caps on high-value oncology drugs raise the recurring debate on whether aggressive price regulation deters pharmaceutical R&D investment or MNC market entry in India.
- Trade-margin regulation as a policy innovation: Unlike blunt price-ceiling tools, TMR targets distribution-chain inefficiency specifically — a nuanced instrument worth distinguishing from NLEM-based price control.
- Catastrophic health expenditure: Cancer treatment is a leading cause of out-of-pocket catastrophic health spending in India; this measure directly addresses SDG 3 (health) and India's Ayushman Bharat/universal health coverage goals.
- Expert-committee-based policymaking: Basing the 137-drug list on a DGHS oncologist panel's recommendation is a model for evidence-based regulatory decision-making.
- Awareness and last-mile delivery gap: As AIIMS Guwahati itself flags, a price cut only helps patients if awareness and pharmacy-level compliance follow — a reminder that policy announcement and implementation are distinct challenges.
Possible Mains question
**GS2, 10 marks:** "Trade Margin Rationalisation is a more targeted alternative to direct price control for making costly medicines affordable. Discuss with reference to the 2026 anti-cancer drug price revision."
Related topics
- National List of Essential Medicines (NLEM) and the DPCO price-control mechanism
- Ayushman Bharat–PM-JAY and catastrophic health expenditure
- Compulsory licensing and patent-pricing debates in pharmaceuticals
- Pharma Sahi Daam and other price-transparency citizen platforms
Topics: GS2
All current affairs of 18 October 2026 → · UPSC Current Affairs